title: Efficacy of switching from premixed insulin to insulin glargine regimen in Type 2 diabetes mellitus patients with different islet functions.
abstract: The present study evaluated the efficacy of switching from premixed insulin or an insulin analogue to insulin glargine plus oral antidiabetic drugs (OADs) in patients with type 2 diabetes mellitus (T2DM). The feasibility and suitability of the regimen to the patients was examined based on islet function. Patients with T2DM (n=30) treated with stable doses of premixed insulin or an insulin analogue for eight weeks were divided into two groups according to islet function. Group A had a 2 h of C peptide (2hCP)/fasting C peptide (FCP) ratio ≤3, whereas group B had a 2hCP/FCP ratio >3. Eight weeks following the switch to insulin glargine plus OADs, a significant decrease in fasting blood glucose (FBG), 2 h postprandial blood glucose (2hPBG) and glycosylated‑haemoglobin (HbA1c) were observed in the two groups, with effective rates of 75, 42.9 and 39.3%, respectively. A distinct reduction in the insulin dose was particularly evident in group B. There was a marked decrease in FBG in group A, more so than that observed in group B. By contrast, the decrease in HbA1c was more evident in group B following the switch. A larger number of patients in group B had HbA1c≤7.0%, compared with group A. No difference in the incidence of hypoglycaemia and change of body weight were observed. Following the switch to insulin glargine plus OADs, patients with T2DM demonstrated improved blood glucose control and reduced insulin dosage. The results revealed that this switch in regimen is more suitable for patients with T2DM with 2hCP/FCP>3 and that administration of insulin glargine plus OADs is more efficacious for patients with T2DM with increased FBG levels.
authors.affiliation: Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116002, P.R. China.
authors.forename: Yong-Bo
authors.initials: YB
authors.lastname: Wang
authors.affiliation: Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116002, P.R. China.
authors.forename: Shuang
authors.initials: S
authors.lastname: Wang
authors.affiliation: Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116002, P.R. China.
authors.forename: Ran
authors.initials: R
authors.lastname: Bai
authors.affiliation: Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116002, P.R. China.
authors.forename: Jian-Ling
authors.initials: JL
authors.lastname: Du
authors.affiliation: Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116002, P.R. China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Xing
authors.affiliation: Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116002, P.R. China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Ba
authors.affiliation: Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116002, P.R. China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116002, P.R. China.
authors.forename: Xue-Yan
authors.initials: XY
authors.lastname: Zhang
authors.affiliation: Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116002, P.R. China.
authors.forename: Chun-Hong
authors.initials: CH
authors.lastname: Shi
authors.affiliation: Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116002, P.R. China.
authors.forename: Jun-Jie
authors.initials: JJ
authors.lastname: Yao
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting / Q000627:therapeutic use*; D007515:Islets of Langerhans / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting